A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

Trial Profile

A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs IMO 2125 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 25 Sep 2017 Planned number of patients changed from 40 to 75.
    • 12 May 2017 Status changed from not yet recruiting to recruiting.
    • 11 Apr 2017 According to an Idera Pharmaceuticals media release, patient enrollment has been activated in this trial and the first patient is expected to enroll early this quarter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top